Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 19, 2022CancersOpen Access

Anaplastic Thyroid Carcinoma: An Update

View Full Paper
Ask AI
Bookmark
Share

Authors

AJArnaud JanninCentre National de la Recherche ScientifiqueAEAlexandre EscandeCentre Léon BérardAGAbir Al GhuzlanCentre National de la Recherche Scientifique

Discussion

Loading...

Member takes

Implication

Clinical review outlines multimodal management and targeted therapies in anaplastic thyroid carcinoma, suggesting fast-track care pathways can double overall survival.

Key Points

  • To review the clinical characteristics, urgent diagnostic pathways, and multimodal therapeutic strategies for improving survival in anaplastic thyroid carcinoma.
  • Synthesized diagnostic protocols emphasizing expedited expert biopsy reviews alongside immunohistochemical and molecular analyses.
  • Evaluated multidisciplinary treatment sequences encompassing prompt surgery, chemo-radiotherapy, targeted therapies, and decompressive cervical irradiation across disease stages.
  • Median overall survival remains poor under conventional conditions, typically ranging from 4 to 10 months post-diagnosis.
  • Implementation of systematic molecular testing, targeted therapies, and dedicated fast-track tertiary care pathways can double median overall survival.
  • Adjuvant chemo-radiotherapy is indicated for localized post-surgical disease, while locally advanced or metastatic presentations require systemic chemotherapy, targeted agents, or palliative decompressive cervical radiotherapy.

Cite This Study

Jannin et al. (2022) studied this question.

synapsesocial.com/papers/69d817468c03fbaff8bedabdhttps://doi.org/10.3390/cancers14041061
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1<i>EIF1AX</i> and <i>RAS</i> Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC2018 · 93 citations
  2. 2Rationale of the rare cancer list: a consensus paper from the Joint Action on Rare Cancers (JARC) of the European Union (EU)2020 · 78 citations
  3. 3Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany2016 · 124 citations
  4. 4Aggressive Palliation and Survival in Anaplastic Thyroid Carcinoma2015 · 57 citations
  5. 5Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer2021 · 122 citations